Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Cell Transplant. 2011;20(1):95-7. doi: 10.3727/096368910X532800. Epub 2010 Sep 30.
Possible strategies for treating stroke include: 1) thrombolytic therapy with tissue plasminogen activator (tPA): restoring cerebral blood flow in the acute phase of ischemic stroke but sometimes causing hemorrhagic transformation (HT); 2) stem cell therapy: the repair of disrupted neuronal networks with newly born neurons in the chronic phase of ischemic stroke. Firstly, we estimated the vascular protective effect of a free radical scavenger, edaravone, in the tPA-treated rat model of middle cerebral artery occlusion. Edaravone prevented dramatically decreased the hemorrhagic transformation and improved the neurologic score and survival rate of tPA-treated rats. Secondly, we attempted to restore brain tissue using a novel biomaterial, polydimethysiloxane-tetraethoxysilane (PDMS-TEOS) hybrid with or without vascular endothelial growth factor (VEGF), and we could show that implantation of a PDMS-TEOS scaffold with VEGF might be effective for treating old brain infarction or trauma. In the future, we will combine these strategies to develop more effective therapies for treatment of strokes.
1)组织型纤溶酶原激活物(tPA)的溶栓治疗:恢复缺血性中风急性期的脑血流,但有时会导致出血性转化(HT);2)干细胞治疗:在缺血性中风的慢性期,通过新生成的神经元修复受损的神经网络。首先,我们评估了自由基清除剂依达拉奉在 tPA 治疗的大脑中动脉闭塞大鼠模型中的血管保护作用。依达拉奉可显著防止出血性转化,并改善 tPA 治疗大鼠的神经评分和存活率。其次,我们尝试使用一种新型生物材料聚二甲基硅氧烷-四乙氧基硅烷(PDMS-TEOS)混合物(有或没有血管内皮生长因子(VEGF))来恢复脑组织,我们可以表明,植入含有 VEGF 的 PDMS-TEOS 支架可能对治疗陈旧性脑梗死或创伤有效。未来,我们将结合这些策略,开发更有效的中风治疗方法。